Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors

Background Immune checkpoint blockade (ICB) is a clinically proven concept to treat cancer. Still, a majority of patients with cancer including those with poorly immune infiltrated ‘cold’ tumors are resistant to currently available ICB therapies. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)...

Full description

Saved in:
Bibliographic Details
Main Authors: Laetitia Fend, Eric Quemeneur, Monika Semmrich, Jean-Baptiste Marchand, Matilda Rehn, Nathalie Silvestre, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Björn Frendeus, Petra Holmkvist, Carolin Svensson, Christelle Remy, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L Cleary, Mimoza Bodén
Format: Article
Language:English
Published: BMJ Publishing Group 2022-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/1/e003488.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items